Literature DB >> 10321796

Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action.

W Löscher1.   

Abstract

Valproate is currently one of the major antiepileptic drugs with efficacy for the treatment of both generalized and partial seizures in adults and children. Furthermore, the drug is increasingly used for therapy of bipolar and schizoaffective disorders, neuropathic pain and for prophylactic treatment of migraine. These various therapeutic effects are reflected in preclinical models, including a variety of animal models of seizures or epilepsy. The incidence of toxicity associated with the clinical use of valproate is low, but two rare toxic effects, idiosyncratic fatal hepatotoxicity and teratogenicity, necessitate precautions in risk patient populations. Studies from animal models on structure-relationships indicate that the mechanisms leading to hepatotoxicity and teratogenicity are distinct and also differ from the mechanisms of anticonvulsant action of valproate. Because of its wide spectrum of anticonvulsant activity against different seizure types, it has repeatedly been suggested that valproate acts through a combination of several mechanisms. As shown in this review, there is substantial evidence that valproate increases GABA synthesis and release and thereby potentiates GABAergic functions in some specific brain regions, such as substantia nigra, thought to be involved in the control of seizure generation and propagation. Furthermore, valproate seems to reduce the release of the epileptogenic amino acid gamma-hydroxybutyric acid and to attenuate neuronal excitation induced by NMDA-type glutamate receptors. In addition to effects on amino acidergic neurotransmission, valproate exerts direct effects on excitable membranes, although the importance of this action is equivocal. Microdialysis data suggest that valproate alters dopaminergic and serotonergic functions. Valproate is metabolized to several pharmacologically active metabolites, but because of the low plasma and brain concentrations of these compounds it is not likely that they contribute significantly to the anticonvulsant and toxic effects of treatment with the parent drug. By the experimental observations summarized in this review, most clinical effects of valproate can be explained, although much remains to be learned at a number of different levels of valproate's mechanisms of action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321796     DOI: 10.1016/s0301-0082(98)00075-6

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  103 in total

1.  Response to flumazenil in the late luteal phase and follicular phase of the menstrual cycle in healthy control females.

Authors:  Emily C Bell; Glen B Baker; Christina Poag; Francois Bellavance; Janisse Khudabux; Jean-Michel Le Mellédo
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

Review 2.  Epigenetic GABAergic targets in schizophrenia and bipolar disorder.

Authors:  A Guidotti; J Auta; Y Chen; J M Davis; E Dong; D P Gavin; D R Grayson; F Matrisciano; G Pinna; R Satta; R P Sharma; L Tremolizzo; P Tueting
Journal:  Neuropharmacology       Date:  2010-11-11       Impact factor: 5.250

Review 3.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

4.  Valproate blocks high-dose methamphetamine-induced behavioral cross-sensitization to locomotion-inducing effect of dizocilpine (MK-801), but not methamphetamine.

Authors:  K Ito; T Abekawa; T Koyama
Journal:  Psychopharmacology (Berl)       Date:  2006-04-01       Impact factor: 4.530

5.  The neuroprotective effect of curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate.

Authors:  Heba S Aboul Ezz; Yasser A Khadrawy; Neveen A Noor
Journal:  Neurochem Res       Date:  2011-07-13       Impact factor: 3.996

Review 6.  Central mechanism of action of antimigraine prophylactic drugs.

Authors:  Gerardo Casucci; Veronica Villani; Fabio Frediani
Journal:  Neurol Sci       Date:  2008-05       Impact factor: 3.307

7.  An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability.

Authors:  L Tremolizzo; G Carboni; W B Ruzicka; C P Mitchell; I Sugaya; P Tueting; R Sharma; D R Grayson; E Costa; A Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

8.  QPEEG analysis of the effects of sodium valproate on adult Chinese patients with generalized tonic-clonic seizures.

Authors:  Jiamei Guo; Dan Wang; Min Ren; Bo Xiong; Zengyou Li; Xuefeng Wang; Kebin Zeng
Journal:  Metab Brain Dis       Date:  2014-05-10       Impact factor: 3.584

9.  Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice.

Authors:  Anti Kalda; Lenne-Triin Heidmets; Hai-Ying Shen; Alexander Zharkovsky; Jiang-Fan Chen
Journal:  Behav Brain Res       Date:  2007-03-31       Impact factor: 3.332

10.  The mood stabilizer valproate inhibits both inositol- and diacylglycerol-signaling pathways in Caenorhabditis elegans.

Authors:  Suzumi M Tokuoka; Adolfo Saiardi; Stephen J Nurrish
Journal:  Mol Biol Cell       Date:  2008-02-20       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.